IR780 and aluminum hydroxide-loaded nanoparticles and preparation method and application thereof

Through the selective accumulation of IR780 and aluminum hydroxide nanoparticles and deep tumor penetration, combined with photoacoustic kinetic therapy, the problem of inability to significantly inhibit cervical cancer recurrence and metastasis in the prior art was solved, and significant anti-tumor effect was achieved. The immune response is enhanced.

CN115813883BActive Publication Date: 2024-11-12THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211639487.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-12-20
Publication Date
2024-11-12
Estimated Expiration
2042-12-20

AI Technical Summary

Technical Problem

Existing combined photoacoustic dynamic therapy and immunotherapy cannot significantly inhibit tumor recurrence and distant metastasis in the treatment of cervical cancer, and lacks selective accumulation and deep tumor penetration of nanoparticle substances.

Method used

IR780 and aluminum hydroxide nanoparticles are used to carry IR780 and aluminum hydroxide nanoparticles, and the core is oxygen-carrying perfluoropentane and the shell is a core-shell structure of polylactic acid-glycolic acid. It is prepared by W/O/W dual emulsification method. IR780 is used as photosensitizer and hydroxide oxidation. Aluminum acts as an antigen capture agent to achieve selective accumulation of nanoparticles and deep tumor penetration, combining photoacoustic dynamics therapy and immunotherapy.

Benefits of technology

Significantly inhibit primary tumor growth and tumor metastasis, enhance anti-tumor immune response, improve anti-tumor treatment effect, and realize the integration of diagnosis and treatment of cervical cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115813883B_ABST
    Figure CN115813883B_ABST
Patent Text Reader

Abstract

The present invention provides IR780 and aluminum hydroxide loaded nanoparticles and their preparation method and application. It comprises a core-shell structure, wherein the core is oxygen-carrying perfluoropentane, the shell is polylactic-glycolic acid, and the polylactic-glycolic acid is loaded with IR780 and aluminum hydroxide. The present invention achieves cancer treatment through powerful synergistic effects, including selective accumulation and deep tumor penetration of IR780 and aluminum hydroxide loaded nanoparticles, ICD-induced immune response and antigen capture. Based on the core principle of anticancer immunotherapy, this combined treatment method shows a significant reduction in primary tumor growth and tumor metastasis progression.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of nano preparations, and in particular to IR780 and aluminum hydroxide-loaded nano particles and a preparation method and application thereof. Background Art

[0002] Over the past decade, cervical cancer has become one of the most common gynecological cancers and a leading cause of cancer-related morbidity and mortality in women worldwide, with an estimated 600,000 new cases and 300,000 deaths each year. The conventional treatment strategy for most patients with cervical cancer is surgery. In addition, as the disease progresses, radiotherapy and chemotherapy are also utilized. Cervical cancer still causes high mortality, with a 5-year overall survival rate well below 65%. In addition, recurrence is an increasing challenge for cervical cancer as 30-40% of cervical cancer patients demonstrate (show) cervical cancer recurrence. Considering that cervical cancer remains a life-threatening disease, sensitive methods for its diagnosis and new strategies for treatment need to be highly valued.

[0003] With the increased understanding of cancer and its interaction with the immune system, cancer immunotherapy has made tremendous progress and shows promise as a new therapeutic strategy for antitumor treatment. Emerging evidence suggests that the additional involvement of the immune response in particular contributes to the excessive antitumor efficacy of cancer treatments, and certain chemotherapeutic drugs (such as oxaliplatin, anthracyclines, and cyclophosphamide) and exogenous stimuli (such as photodynamic therapy and photothermal therapy) trigger immunogenic cell death (ICD) by inducing the release of tumor-derived protein antigens (TDPA) from dying tumor cells, which can activate dendritic cells (DCs) expressing a series of receptors. ICD can induce immune responses by exposing or releasing molecules such as chemokines, cytokines, tumor-associated antigens (TAAs), and damage-associated molecular patterns (DAMPs), including exposure of cell surface calreticulin (CRT) and release of adenosine triphosphate (ATP), as well as translocation of high-mobility group box 1 (HMGB1) from the nucleus to the extracellular matrix, thereby initiating a cascade of immune responses, such as increasing levels of related cytokines and stimulating antigen presentation by dendritic cells (DCs). Given the low tumor immunogenicity and immunosuppressive nature of the tumor microenvironment (TME), antigen capture enhancement is extremely important in addition to improving the response rate of tumor immunotherapy.

[0004] Photodynamic therapy (PDT), which involves three elements: photosensitizer (PS), molecular oxygen, and light irradiation of appropriate wavelength, has been well studied as an effective therapeutic option for anticancer treatment. However, PDT alone is often limited by penetration depth and hypoxia in solid tumors. Therefore, sonodynamic therapy (SDT) shows various benefits, such as deeper tissue penetration, minimal invasiveness, and local cytotoxicity when the sonosensitizer accumulates at the tumor site and is activated by ultrasound, which can overcome the limitations of PDT. It has been shown that both PDT and SDT, the two most popular methods for triggering immune responses, can effectively produce ICD. In addition, the combined application of PDT and SDT (called PDST) can contribute to high-precision and sufficient reactive oxygen species (ROS) generation in the target lesion area, which leads to further cytotoxicity, thereby inducing cell apoptosis and necrosis to achieve therapeutic purposes.

[0005] Combined photoacoustic dynamic therapy (PSDT) and immunotherapy have shown great potential in the treatment of metastatic cancer. However, the above combined strategy still cannot significantly inhibit tumor recurrence and distant metastasis. At present, there are no reports on the combined photoacoustic dynamic therapy and immunotherapy as well as synergistic antigen capture and selective accumulation and deep tumor penetration of targeted nanoparticles for the treatment of cervical cancer. Summary of the invention

[0006] In view of the deficiencies in the prior art, the present invention provides IR780 and aluminum hydroxide loaded nanoparticles and applications thereof, which provide a new method for treating cervical cancer by synergistic antigen capture and selective accumulation of target nanoparticles and deep tumor penetration.

[0007] In one aspect, the present invention provides IR780 and aluminum hydroxide loaded nanoparticles, comprising a core-shell structure, wherein the core is oxygen-carrying perfluoropentane, the shell is polylactic acid-glycolic acid, and IR780 and aluminum hydroxide are loaded on the polylactic acid-glycolic acid.

[0008] Furthermore, the hydrodynamic diameter of the IR780 and aluminum hydroxide-loaded nanoparticles is 257.133±3.82 nm, and the surface potential is 21.97±0.75 mV.

[0009] Furthermore, the encapsulation efficiency of aluminum hydroxide in the IR780 and aluminum hydroxide nanoparticles was 14.19±1.45%, and the drug loading was 0.27±0.03%; the encapsulation efficiency of IR780 was 79.53±0.47%, and the drug loading was 2.93±0.071%.

[0010] In another aspect, the present invention provides a method for preparing IR780 and aluminum hydroxide-loaded nanoparticles, which is prepared by a W / O / W double emulsification method, comprising the following steps:

[0011] S1: dissolving polylactic acid-glycolic acid and IR780 in dichloromethane, and then adding oxygen-carrying perfluoropentane and aluminum hydroxide aqueous solution for emulsification to obtain a primary emulsion;

[0012] S2: dissolving the primary emulsion obtained in step S1 in a polyvinyl alcohol aqueous solution, and emulsifying again to obtain a mixed emulsion; stirring and centrifuging the mixed emulsion to obtain IR780 and aluminum hydroxide-loaded nanoparticles.

[0013] Furthermore, the usage ratio of polylactic acid-glycolic acid, IR780 and dichloromethane is 50-100:1-2:2 in mg / mg / ml.

[0014] Furthermore, the concentration of the aluminum hydroxide aqueous solution is 1 mg / ml, and the volume ratio of oxygen-carrying perfluoropentane, the aluminum hydroxide aqueous solution, and dichloromethane is 0.2-0.3:1-2:2.

[0015] Furthermore, the concentration of the polyvinyl alcohol aqueous solution is 5%, and the volume ratio of dichloromethane to the polyvinyl alcohol aqueous solution is 2:5-7.

[0016] Furthermore, in step S1 or step S2, the emulsification is performed by ultrasonic emulsification for 3-5 minutes under ice bath conditions.

[0017] In another aspect, the present invention provides a use of IR780 and aluminum hydroxide-loaded nanoparticles in the preparation of drugs for treating tumors.

[0018] Furthermore, the tumor is cervical cancer.

[0019] The technical principle of the present invention is: the present invention treats cervical cancer through local PDST and IR780 and aluminum hydroxide nanoparticles (OIRAI-NPs) with antigen capture potential.

[0020] Specifically, the present invention uses polylactic-co-glycolic acid (PLGA) as an encapsulating polymer and IR780 as a photosensitizer to allow perfluoropentane (PFP) to be used as a phase-change contrast agent carrying oxygen.

[0021] Aluminum hydroxide nanoparticles, as adjuvants for capturing antigens, can efficiently adsorb antigens and gradually release them, increasing the effect of antigen presenting cells (APC) on antigen uptake and inducing tumor-specific immune responses.

[0022] Compared with traditional photosensitizers (i.e., indocyanine green), IR780 showed higher photostability, fluorescence intensity, ROS generation efficiency, photothermal conversion, and a wider absorption cross section. At the same time, IR780 can selectively accumulate in tumor areas, giving OIRAI-NPs the ability to selectively accumulate and penetrate into tumor tissues. Furthermore, internalized IR780 is mainly concentrated in mitochondria, promoting cancer therapy. Furthermore, the wide absorption cross section of IR780 enables OIRAI-NPs to produce a large amount of 1O under near-infrared (NIR) laser irradiation. 2 and heat to promote phototherapy, thereby enhancing anti-tumor therapy, triggering a higher release of TDPA. Moreover, OIRAI-NPs have the ability to collect and maintain TDPA in situ, which enhances antigen uptake by antigen-presenting cells (APCs) and triggers tumor-specific immune responses.

[0023] Compared with the prior art, the present invention has the following beneficial effects:

[0024] (1) The present invention achieves cancer treatment through synergistic effects. OIRAI-NPs can not only be used as PSDT media for tumor treatment, but also capture antigens released during treatment to trigger anti-tumor immune responses, induce immunogenic cell death (ICD), and greatly enhance the production of damage-associated molecular patterns (DAMPs).

[0025] (2) The inherent structure of IR780 in the present invention endows OIRAI-NPs with mitochondrial targeting ability, and OIRAI-NPs with aluminum hydroxide as an antigen capture agent improve the uptake of tumor antigens by dendritic cells (DCs). At the same time, the combined application of IR780 and aluminum hydroxide has a synergistic effect, which jointly promotes the anti-tumor effect of IR780 and aluminum hydroxide nanoparticles.

[0026] (3) OIRAI-NPs have great potential as contrast agents in enhancing photoacoustic (PA) and ultrasound imaging.

[0027] In summary, based on the core principle of anticancer immunotherapy, the combined treatment method of the present invention can significantly inhibit primary tumor growth and tumor metastasis progression, and can become a potential nanoplatform for cancer treatment. This combined strategy is expected to significantly improve anti-tumor immunity and achieve integrated diagnosis and treatment of cervical cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 This is a transmission electron microscopy image of OIRAI-NPs in Example 1 of the present invention.

[0029] Figure 2 This is a graph showing the average particle size of OIRAI-NPs in Example 1 of the present invention.

[0030] Figure 3 This is the XPS result diagram of OIRAI-NPs in Example 1 of the present invention.

[0031] Figure 4 This is a graph showing the UV spectrophotometer detection results of OIRAI-NPs in Example 1 of the present invention.

[0032] Figure 5 This is a standard curve diagram of IR780 in OIRAI-NPs in Example 1 of the present invention.

[0033] Figure 6 These are the ultraviolet absorption spectra of free IR780, OIRAI-NPs, OIR-NPs, OAI-NPs, and O-NPs in Example 1 of the present invention.

[0034] Figure 7 This is the optical stability of IR780 and OIRAI-NPs in Example 1 of the present invention.

[0035] Figure 8 This is the in vitro photoacoustic imaging of OIRAI-NPs, OIR-NPs, OAI-NPs and PBS in Example 2 of the present invention.

[0036] Fig. 9 This is the in vitro photothermal imaging of OIRAI-NPs in Example 3 of the present invention.

[0037] Fig.10 This is a diagram showing the phagocytic effect of TC-1 cells on OIRAI-NPs nanoparticles and the effect of OIRAI-NPs targeting TC-1 cell mitochondria observed under a laser confocal scanning microscope in Experimental Example 1 of the present invention.

[0038] Fig.11 This is a graph showing the biosafety test results of OIRAI-NPs on TC-1 cells in Experimental Example 1 of the present invention.

[0039] Fig.12 This is a graph showing the cytotoxicity results of OIRAI-NPs, OIR-NPs, OAI-NPs, and PBS on TC-1 cells in Experimental Example 1 of the present invention.

[0040] Fig.13 This is a graph showing the killing effect on TC-1 cells after different treatments in Experimental Example 1 of the present invention.

[0041] Fig.14 This is a graph showing the generation of ROS in TC-1 cells after different treatments in Experimental Example 2 of the present invention.

[0042] Fig.15 This is a diagram showing the damage results at the subcellular level of TC-1 cells after different treatments in Experimental Example 3 of the present invention.

[0043] Fig.16 This is a graph showing the results of promoting the maturation of dendritic cells (DCs) after different treatments in Experimental Example 4 of the present invention. DETAILED DESCRIPTION

[0044] The technical solution of the present invention is further described below in conjunction with the accompanying drawings and embodiments. Aluminum hydroxide nanoparticles were provided by Xi'an Ruixi Biotechnology Co., Ltd. (Xi'an, China).

[0045] Example 1 Preparation of IR780 and aluminum hydroxide loaded nanoparticles

[0046] Mitochondria-targeted IR780 and aluminum hydroxide loaded nanoparticles (OIRAI-NPs) were prepared by double emulsification method (water / oil / water). The specific steps are as follows:

[0047] S1: 1 mg Al(OH)3 was dissolved in 1 ml double distilled water (1 mg / ml), 50 mg PLGA and 1 mg IR780 were mixed and then completely dissolved in 2 ml dichloromethane (DCM). After that, 200 μl PFP and 1 ml Al(OH)3 (1 mg / ml) were added to the mixture and the mixture was emulsified for 3 minutes in an ice bath at 35 W power (5 s on and 5 s off) using a sonicator (HeatSystem Inc, USA).

[0048] S2: The mixture was dissolved in 5 ml of polyvinyl alcohol aqueous solution (5%) and sonicated for an additional 3 minutes at 35 W (5 s on and 5 s off). The resulting emulsion was magnetically mixed and stirred for 4 hours to remove DCM (ice bath), and then centrifuged at 10000 rpm for 5 minutes, three times, and washed with deionized water after each centrifugation, and then the prepared nanoparticles were suspended in deionized water. All operations were carried out in a completely dark ice bath.

[0049] Nanoparticles without aluminum hydroxide loading (OIR-NPs), nanoparticles without IR780 loading (OAI-NPs), and nanoparticles without IR780 and aluminum hydroxide loading (O-NPs) were prepared by the same method.

[0050] Transmission electron microscopy observation shows that the multifunctional composite nanoparticles OIRAI-NPs have a uniform spherical structure ( Figure 1) and can be evenly dispersed in double distilled water. The average particle size and surface potential of OIRAI-NPs, OIR-NPs, OAI-NPs, and O-NPs were measured by particle size and Zeta potential analyzer. The hydrodynamic diameter of OIRAI-NPs, a multifunctional composite nanoparticle loaded with IR780 and aluminum hydroxide, was 257.133±3.82nm ( Figure 2 ), with a surface potential of 21.97±0.75mV. The average particle size of nanoparticles not loaded with aluminum hydroxide (OIR-NPs) was 213.3±3.90nm, and the surface potential was -5.74±0.58mV. The average particle size of nanoparticles not loaded with IR780 (OAI-NPs) was 226.03±0.68nm, and the surface potential was 3.76±0.57mV. The average particle size of nanoparticles not loaded with IR780 and aluminum hydroxide (O-NPs) was 209.86±4.49nm, and the surface potential was -11.77±0.25Mv.

[0051] Inductively coupled plasma emission spectrometer (ICP-OES) was used to detect the encapsulation efficiency and drug loading of aluminum hydroxide in OIRAI-NPs and OAI-NPs. The encapsulation efficiency of aluminum hydroxide in OIRAI-NPs nanoparticles was 14.19±1.45%, and the drug loading was 0.27±0.03%. The encapsulation efficiency of aluminum hydroxide in nanoparticles OAI-NPs was 4.67±0.32%, and the drug loading was 0.09±0.01%. The aluminum content of both nanoparticles met the safety limit standards for aluminum adjuvants (1.25 mg / dose in the World Health Organization and the European Union, 0.85 mg / dose in the United States, and 0.35-3.0 mg / mL in China). -1 ). XPS detection further confirmed the successful encapsulation of aluminum hydroxide in OIRAI-NPs ( Figure 3 ).

[0052] The UV spectrophotometer detected a strong absorption peak of OIRAI-NPs at 780 nm ( Figure 4 ), according to the standard curve of IR780 ( Figure 5 ) The encapsulation efficiency of IR780 in OIRAI-NPs was calculated to be 79.53±0.47%, and the drug loading was 2.93±0.071%; the encapsulation efficiency of IR780 in OIR-NPs was 71.92±0.193%, and the drug loading was 2.75±0.01%. The UV absorption spectra of free IR780 and OIRAI-NPs, OIR-NPs, OAI-NPs, and O-NPs showed that IR780 was successfully encapsulated in the nanoparticles ( Figure 6 ).

[0053] Since IR780 is insoluble in water, a higher encapsulation efficiency in nanoparticles can avoid the quenching of IR780 and increase its stability, thus improving its application in biological tissues, e.g. Figure 7 As shown in the results, the optical stability of IR780 decreased significantly within 14 days, while the optical stability of OIRAI-NPs did not change much. In addition, the stability of OIRAI-NPs dispersed in double distilled water was good, and its particle size did not change significantly within 30 days at 4°C.

[0054] Example 2 In vitro imaging of IR780 and aluminum hydroxide loaded nanoparticles

[0055] The nanoparticles OIRAI-NPs, OIR-NPs, OAI-NPs and PBS prepared in Example 1 were subjected to in vitro photoacoustic imaging. The images before and after PSDT treatment are as follows: Figure 8 As shown:

[0056] Depend on Figure 8 Analysis showed that the PBS group after PSDT treatment had no imaging enhancement in B mode, CEUS mode and PA mode. The OAI-NPs group after PSDT treatment had imaging enhancement in B mode and CEUS mode, but no obvious imaging enhancement in PA mode. This phenomenon may be due to the slight heat generation after near-infrared laser irradiation after PSDT treatment, which caused the phase change of OAI-NPs. The ultrasound signals of the OIRAI-NPs and OIR-NPs groups were significantly enhanced in B mode, CEUS mode and PA mode compared with other groups, that is, the near-infrared light excitation IR780 caused the nanoparticle temperature to rise, and the PFP in the nanoparticles was vaporized in large quantities when the temperature exceeded a certain temperature (49°C), resulting in enhanced multimodal imaging.

[0057] Different from acoustic droplet vaporization (ADV), optical droplet vaporization (OVD) uses laser to irradiate nanoparticles, where the light absorbers absorb light energy and convert it into heat energy, eventually causing the PFP inside the nanoparticles to vaporize. The experimental results show the successful encapsulation of oxygen-carrying perfluoropentane (PFP) in phase change materials, and also lay the foundation for subsequent dual-modality imaging.

[0058] Example 3 In vitro photothermal effect of IR780 and aluminum hydroxide nanoparticles

[0059] Laser (irradiation condition: 1.5W / cm 2 After irradiation of OIRAI-NPs for 5 min, the temperature rise rate of OIRAI-NPs was positively correlated with the concentration, while the temperature of the control group, i.e., the PBS group, remained basically unchanged ( Fig. 9 ).

[0060] An efficient photothermal converter is a prerequisite for optical droplet vaporization (OVD). The experimental results verified the potential of OIRAI-NPs as a photothermal converter. Studies have reported that tumor cells will undergo cell ablation after being continuously exposed to high temperatures for a certain period of time. Therefore, the experimental results show that OIRAI-NPs have certain anti-tumor potential.

[0061] Experimental Example 1 In vitro phagocytosis and killing experiment of IR780 and aluminum hydroxide nanoparticles

[0062] Effective intracellular uptake of OIRAI-NPs is a prerequisite for improving their ability to kill TC-1 tumor cells. After DiI-labeled OIRAI-NPs, OIR-NPs, OAI-NPs and PBS were co-incubated with cervical cancer cells TC-1 for 4 hours, it was observed under laser confocal scanning microscopy (CLSM) that DiI-labeled OIRAI-NPs efficiently accumulated in TC-1 tumor cells and targeted the mitochondria of TC-1 tumor cells ( Fig.10 ). It was further found that OIRAI-NPs had no toxic effect on tumor cells within a concentration of 5.0 mg / ml, as shown by CCK8 ( Fig.11 ).

[0063] The killing effect of OIRAI-NPs nanoparticles on TC-1 tumor cells was further observed. Tumor cells were treated with different groups, as follows: Control group, OIRAI-NPs group, OIR-NPs group, OAI-NPs group, Control+PSDT group, OIRAI-NPs+PSDT group, OIR-NPs+PSDT group, OAI-NPs+PSDT group, etc. The Control group and OAI-NPs group had almost no killing effect on tumor cells, the OIR-NPs group had a very small killing effect on tumor cells, and the OIRAI-NPs+PSDT group had the greatest killing effect on tumor cells, which was significantly better than the OIR-NPs+PSDT group and the OAI-NPs+PSDT group. For example, CCK8( Fig.12 ) as shown. This shows that IR780 and aluminum hydroxide have a synergistic effect in killing tumors. The laser confocal scanning microscopy image is shown in Fig.13 shown.

[0064] Experimental Example 2 Active oxygen generation capacity of IR780 and aluminum hydroxide nanoparticles

[0065] After being treated with PSDT, the tumor cells that had engulfed the nanoparticles OIRAI-NPs and OIR-NPs had a significant increase in intracellular reactive oxygen species, which, after binding to the 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA) probe, could be converted into fluorescent 2,7-dichlorofluorescein (DCF), showing strong green fluorescence under CLSM. Fig.14 As shown in the figure, the interference effect of nanoparticles alone (control group) or PSDT-treated cells (control+PSDT group) on ROS was limited. In contrast, the ROS levels of the OIRAI-NPs+PSDT group and the OIR-NPs+PSDT group increased, and the ROS level of the OIRAI-NPs+PSDT group increased most significantly, significantly higher than that of the OIR-NPs+PSDT group. Strong green fluorescence was observed from the DCF channel, which also confirmed the significant therapeutic effect of our OIRAI-NPs+PSDT group.

[0066] Experimental Example 3 Subcellular damage level of IR780 and aluminum hydroxide nanoparticles

[0067] The groups were as follows: Control group, OIRAI-NPs group, OIR-NPs group, Control+PSDT group, OIRAI-NPs+PSDT group, and OIR-NPs+PSDT group. The cell damage induced by different groups was further evaluated by the JC-1 assay kit. JC-1 is a membrane permeable probe used to analyze the state of cell apoptosis based on monitoring the mitochondrial membrane potential (MMP). After mitochondrial damage leads to MMP depolarization, JC-1 aggregates (λem: 585nm) may diffuse from the organelles into the cytoplasm and decompose into JC-1 monomers (λem: 115nm), which is the fluorescence change from red to green. Fig.15 As shown in the figure, no mitochondrial damage was observed without PSDT treatment; after PSDT treatment, the Control+PSDT group produced almost no green fluorescence, and the OIR-NPs+PSDT group produced a small to moderate amount of green fluorescence. The OIR-NPs+PSDT group produced a large amount of green fluorescence, indicating a decrease in mitochondrial membrane potential and that tumor cells were in the early stages of apoptosis.

[0068] IR780 endows OIRAI-NPs with the ability to selectively aggregate in tumor tissues and penetrate deep into tumor tissues. In addition, with the help of IR780, OIRAI-NPs can further aggregate in mitochondria.

[0069] Experimental Example 4: IR780 and aluminum hydroxide nanoparticles combined with PSDT treatment promote the maturation of dendritic cells

[0070] In the Transwell experiment, the expression of co-stimulatory molecules on DC cells was used to evaluate whether the nanoparticles that captured tumor antigens could effectively promote DC maturation. Fig.16 The results showed that compared with the control group, the expression of CD80 / CD86 in the OIRAI-NPs+PSDT group increased significantly and was significantly higher than that in the OIR-NPs+PSDT group.

[0071] The recognition, processing and presentation of antigens by APCs is the first stage (induction stage) of anti-tumor immune response. Dendritic cells (DCs), as professional antigen-presenting cells, are key initiators of acquired immune responses by capturing and cross-presenting antigens released by tumor cells and activating T cells. It can be seen that OIRAI-NPs combined with photoacoustic therapy can achieve full exposure of tumor antigens, effectively induce DC maturation, promote antigen processing and presentation, and thus activate anti-tumor immune response.

[0072] Comparative Example

[0073] Nanoparticles PIAO-NPs were prepared by the method of Example 1 in CN115192707A. The effect of PIAO-NPs nanoparticles combined with PSDT treatment on dendritic cell maturation was evaluated according to the method of Test Example 4. The test results showed that the expression of CD80 / CD86 in the PIAO-NPs+PSDT group was 50.8, which was significantly lower than the expression of 74.8 in the OIRAI-NPs+PSDT group. This shows that relative to the nanoparticles PIAO-NPs in CN115192707A, the nanoparticles OIRAI-NPs prepared in Example 1 have a stronger effect of activating tumor immune response. In addition, the nanoparticles in CN115192707A use indocyanine green (ICG) and the chemotherapy drug oxaliplatin. Although indocyanine green can be used for photoacoustic imaging and photothermal therapy, ICG is very prone to aggregation and quenching in aqueous solution, has poor stability, no specific functional groups and cell specificity, and in addition, ICG is metabolized very quickly in the body, which limits its application. The near-infrared (NIR) dye IR780 shows excellent photosensitivity, and the combined use of IR780 and aluminum hydroxide has a synergistic effect, which jointly promotes the anti-tumor effect of IR780 and aluminum hydroxide nanoparticles. The chemotherapy drug oxaliplatin can cause side effects such as neurotoxicity, blood and gastrointestinal toxicity, neutropenia, nausea and vomiting, which limit its application range and therapeutic effect. However, this application does not use chemotherapy drugs, avoids the side effects of chemotherapy drugs, and has a wider range of applications.

[0074] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the purpose and scope of the technical solution of the present invention, which should be included in the scope of the claims of the present invention.

Claims

1. A nanoparticle loaded with IR780 and aluminum hydroxide, which has a core-shell structure, wherein the core is oxygen-carrying perfluoropentane, the shell is polylactic acid-glycolic acid, and IR780 and aluminum hydroxide are loaded on the polylactic acid-glycolic acid; The IR780 and aluminum hydroxide nanoparticles are prepared by a W / O / W double emulsification method, comprising the following steps: S1: dissolving polylactic acid-glycolic acid and IR780 in dichloromethane, and then adding oxygen-carrying perfluoropentane and aluminum hydroxide aqueous solution for emulsification to obtain a primary emulsion; S2: dissolving the primary emulsion obtained in step S1 in a polyvinyl alcohol aqueous solution, and emulsifying again to obtain a mixed emulsion; stirring and centrifuging the mixed emulsion to obtain IR780 and aluminum hydroxide-loaded nanoparticles; Calculated in mg / mg / ml, the dosage ratio of polylactic acid-glycolic acid, IR780 and dichloromethane is 50-100:1-2:2; the concentration of aluminum hydroxide aqueous solution is 1 mg / ml, and the volume ratio of oxygen-carrying perfluoropentane, aluminum hydroxide aqueous solution and dichloromethane is 0.2-0.3:1-2:

2.

2. A method of preparing nanoparticles containing IR780 and aluminum hydroxide as claimed in claim 1, characterized in that: The hydrodynamic diameter of the IR780 and aluminum hydroxide-loaded nanoparticles is 257.133±3.82 nm, and the surface potential is 21.97±0.75 mV.

3. A method of preparing nanoparticles containing IR780 and aluminum hydroxide as claimed in claim 1, characterized in that: The encapsulation efficiency of aluminum hydroxide in the IR780 and aluminum hydroxide nanoparticles is 14.19±1.45%, and the drug loading is 0.27±0.03%; the encapsulation efficiency of IR780 is 79.53±0.47%, and the drug loading is 2.93±0.071%.

4. A method for preparing IR780 and aluminum hydroxide nanoparticles according to any one of claims 1 to 3, characterized in that: The preparation is carried out by W / O / W double emulsification method, comprising the following steps: S1: dissolving polylactic acid-glycolic acid and IR780 in dichloromethane, and then adding oxygen-carrying perfluoropentane and aluminum hydroxide aqueous solution for emulsification to obtain a primary emulsion; S2: dissolving the primary emulsion obtained in step S1 in a polyvinyl alcohol aqueous solution, and emulsifying again to obtain a mixed emulsion; stirring and centrifuging the mixed emulsion to obtain IR780 and aluminum hydroxide-loaded nanoparticles; Calculated in mg / mg / ml, the dosage ratio of polylactic acid-glycolic acid, IR780 and dichloromethane is 50-100:1-2:2; the concentration of aluminum hydroxide aqueous solution is 1 mg / ml, and the volume ratio of oxygen-carrying perfluoropentane, aluminum hydroxide aqueous solution and dichloromethane is 0.2-0.3:1-2:

2.

5. A method for preparing IR780 and aluminum hydroxide nanoparticles as claimed in claim 4, characterized in that: The concentration of the polyvinyl alcohol aqueous solution is 5%, and the volume ratio of dichloromethane to the polyvinyl alcohol aqueous solution is 2:5-7.

6. A method for preparing IR780 and aluminum hydroxide nanoparticles as claimed in claim 4, characterized in that: In step S1 or step S2, the emulsification is performed by ultrasonic emulsification for 3-5 minutes under ice bath conditions.

7. Use of the IR780 and aluminum hydroxide-loaded nanoparticles according to any one of claims 1 to 3 in the preparation of a drug for treating tumors, wherein the tumor is cervical cancer.